 Immunosuppressive Agents
"Immunosuppressive Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
| Descriptor ID |
D007166
|
| MeSH Number(s) |
D27.505.696.477.656
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunosuppressive Agents".
Below are MeSH descriptors whose meaning is more specific than "Immunosuppressive Agents".
This graph shows the total number of publications written about "Immunosuppressive Agents" by people in this website by year, and whether "Immunosuppressive Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 3 | 1 | 4 | | 1996 | 8 | 3 | 11 | | 1997 | 3 | 4 | 7 | | 1998 | 4 | 6 | 10 | | 1999 | 4 | 4 | 8 | | 2000 | 7 | 10 | 17 | | 2001 | 5 | 4 | 9 | | 2002 | 6 | 1 | 7 | | 2003 | 11 | 10 | 21 | | 2004 | 14 | 8 | 22 | | 2005 | 13 | 9 | 22 | | 2006 | 7 | 1 | 8 | | 2007 | 5 | 10 | 15 | | 2008 | 6 | 10 | 16 | | 2009 | 12 | 15 | 27 | | 2010 | 13 | 7 | 20 | | 2011 | 11 | 11 | 22 | | 2012 | 8 | 7 | 15 | | 2013 | 17 | 7 | 24 | | 2014 | 16 | 10 | 26 | | 2015 | 12 | 5 | 17 | | 2016 | 10 | 13 | 23 | | 2017 | 15 | 9 | 24 | | 2018 | 7 | 7 | 14 | | 2019 | 7 | 9 | 16 | | 2020 | 12 | 11 | 23 | | 2021 | 11 | 7 | 18 | | 2022 | 0 | 10 | 10 | | 2023 | 2 | 11 | 13 | | 2024 | 1 | 8 | 9 |
To return to the timeline, click here.
Below are the most recent publications written about "Immunosuppressive Agents" by people in Profiles.
-
Wenderfer SE, Cooper JC. Do we really need cyclophosphamide for lupus nephritis? Pediatr Nephrol. 2024 Nov; 39(11):3193-3200.
-
Chastain DB, Spradlin M, Ahmad H, Henao-Mart?nez AF. Unintended Consequences: Risk of Opportunistic Infections Associated With Long-term Glucocorticoid Therapies in Adults. Clin Infect Dis. 2024 04 10; 78(4):e37-e56.
-
Herman D, Ghazipura M, Barnes H, Macrea M, Knight SL, Silver RM, Montesi SB, Raghu G, Hossain T. Nintedanib Therapy Alone and Combined with Mycophenolate in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: Systematic Reviews and Meta-analysis. Ann Am Thorac Soc. 2024 Mar; 21(3):474-485.
-
Macrea M, Ghazipura M, Herman D, Barnes H, Knight SL, Silver RM, Montesi SB, Raghu G, Hossain T. Rituximab in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis. Ann Am Thorac Soc. 2024 Feb; 21(2):317-327.
-
Raghu G, Montesi SB, Silver RM, Hossain T, Macrea M, Herman D, Barnes H, Adegunsoye A, Azuma A, Chung L, Gardner GC, Highland KB, Hudson M, Kaner RJ, Kolb M, Scholand MB, Steen V, Thomson CC, Volkmann ER, Wigley FM, Burlile D, Kemper KA, Knight SL, Ghazipura M. Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2024 01 15; 209(2):137-152.
-
Wang CS, Sadun RE, Zhou W, Miller KR, Pyle L, Ardoin SP, Bacha C, Hause E, Hui-Yuen J, Ling N, Pereira M, Riebschleger M, Rouster-Stevens K, Sarkissian A, Shalen J, Soulsby W, Twilt M, Wu EY, Lewandowski LB, Wenderfer SE, Cooper JC. Renal Response Outcomes of the EuroLupus and National Institutes of Health Cyclophosphamide Dosing Regimens in Childhood-Onset Proliferative Lupus Nephritis. Arthritis Rheumatol. 2024 Mar; 76(3):469-478.
-
Herman D, Ghazipura M, Barnes H, Macrea M, Knight SL, Silver RM, Montesi SB, Raghu G, Hossain T. Mycophenolate in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis. Ann Am Thorac Soc. 2024 Jan; 21(1):136-150.
-
Barnes H, Ghazipura M, Herman D, Macrea M, Knight SL, Silver RM, Montesi SB, Raghu G, Hossain T. Cyclophosphamide in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis. Ann Am Thorac Soc. 2024 Jan; 21(1):122-135.
-
Wolf AB, Alvarez E, Corboy JR. Comparative Efficacy of Disease-Modifying Treatments for Relapsing Multiple Sclerosis-Variations in Real-World Experience. JAMA Neurol. 2024 Jan 01; 81(1):87.
-
Chu DK, Schneider L, Asiniwasis RN, Boguniewicz M, De Benedetto A, Ellison K, Frazier WT, Greenhawt M, Huynh J, Kim E, LeBovidge J, Lind ML, Lio P, Martin SA, O'Brien M, Ong PY, Silverberg JI, Spergel JM, Wang J, Wheeler KE, Guyatt GH, Capozza K, Begolka WS, Chu AWL, Zhao IX, Chen L, Oykhman P, Bakaa L, Golden D, Shaker M, Bernstein JA, Greenhawt M, Horner CC, Lieberman J, Stukus D, Rank MA, Wang J, Ellis A, Abrams E, Ledford D, Chu DK. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol. 2024 03; 132(3):274-312.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|